We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Speculating in Takeover Targets
ULBI 11.42-4.4%3:59 PM EDT

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: E_K_S12/16/2019 8:31:49 AM
  Read Replies (1) of 7078
FDA OKs CV benefit claim for Amarin's Vascepa
Dec. 13, 2019 4:33 PM ET|About: Amarin Corporation plc (AMRN)|By: Douglas W. House, SA News Editor

As expected, the FDA approves a cardiovascular (CV) benefit claim for Amarin's (NASDAQ: AMRN) Vascepa (icosapent ethyl) based on results from the large-scale REDUCE-IT study.

The approved use is as an adjunct therapy to reduce the risk of CV events in adults with elevated triglyceride levels of 150 milligrams per deciliter or higher. Patients must also have either established cardiovascular disease or diabetes and two or more additional risk factors for cardiovascular disease.

Trading has yet to resume.


Have big speculative position in ACST. They s/d have their Phase III results from FDA this week. ACST has similar drug as AMRN but use krill fish oil. Fingers crossed

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext